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Aims Infarct-remodelled hearts are less amenable to protection against ischaemia/reperfusion. Understanding preservation
of energy metabolism in diseased vs. healthy hearts may help to develop anti-ischaemic strategies effective also in
jeopardized myocardium.
Methods
and results
Isolated infarct-remodelled/sham Sprague–Dawley rat hearts were perfused in the working mode and subjected to
15 min of ischaemia and 30 min of reperfusion. Protection of post-ischaemic ventricular work was achieved by
pharmacological conditioning with sevoflurane. Oxidative metabolism was measured by substrate flux in fatty acid
and glucose oxidation using [3H]palmitate and [14C]glucose. Mitochondrial oxygen consumption was measured in
saponin-permeabilized left ventricular muscle fibres. Activity assays of citric acid synthase, hydroxyacyl-CoA dehydro-
genase, and pyruvate dehydrogenase and mass spectrometry for acylcarnitine profiling were also performed. Six
weeks after coronary artery ligation, the hearts exhibited macroscopic and molecular signs of hypertrophy consistent
with remodelling and limited respiratory chain and citric acid cycle capacity. Unprotected remodelled hearts showed
a marked decline in palmitate oxidation and acetyl-CoA energy production after ischaemia/reperfusion, which nor-
malized in sevoflurane-protected remodelled hearts. Protected remodelled hearts also showed higher b-oxidation flux
as determined by increased oxygen consumption with palmitoylcarnitine/malate in isolated fibres and a lower ratio of
C16:1+C16OH/C14 carnitine species, indicative of a higher long-chain hydroxyacyl-CoA dehydrogenase activity.
Remodelled hearts exhibited higher PPARa-PGC-1a but defective HIF-1a signalling, and conditioning enabled them
to mobilize fatty acids from endogenous triglyceride stores, which closely correlated with improved recovery.
Conclusions Protected infarct-remodelled hearts secure post-ischaemic energy production by activation of b-oxidation and
mobilization of fatty acids from endogenous triglyceride stores.
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1. Introduction
An iconic principle in cardioprotection by metabolic interventions sti-
pulates that increasing fatty acid oxidation under ischaemia/reperfu-
sion conditions is detrimental, while increasing glucose oxidation
and concomitantly reducing fatty acid oxidation (‘Randle cycle’) is
beneficial.1– 3 This concept gained support from many experimental
studies mainly using healthy hearts and is based on seemingly convin-
cing rationales. A number of mechanisms may underlie the benefit of a
reduced reliance on fatty acid oxidation as an energy source and
include oxygen sparing due to the more energetically favourable
glucose (3.17 ATP/O2) relative to fatty acid oxidation (2.83 ATP/
O2), an effect that may be specifically advantageous in stressed
hearts with limited oxygen supply. In addition, fatty acid oxidation is
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known to uncouple electron from proton flux in mitochondria, in-
creasing the formation of reactive oxygen species4 and to uncouple
glycolysis from glucose oxidation, enhancing detrimental proton pro-
duction leading to dysregulation of ionic homeostasis.5 Moreover,
studies with preconditioning, the most effective cardioprotective
strategy, show increased glucose oxidation and decreased fatty acid
oxidation accompanied by improved functional recovery and cell sur-
vival in conditioned hearts, suggesting a causal relationship between
this oxygen-sparing metabolic phenotype and protection.6,7 We
have recently demonstrated that enhanced glucose uptake via
GLUT4 fuels recovery from Ca2+ overload after ischaemia/
reperfusion in rat hearts treated with the preconditioning-mimicking
anaesthetic sevoflurane.8
Post-infarct hypertrophy accounts for a large part of the clinically
relevant cases of left ventricular remodelling in a growing population
of elderly patients.9 The hearts from these patients would benefit
most from protective anti-ischaemic strategies, but unfortunately
appear less amenable to therapy.10 Maladaptive post-infarct remodel-
ling dramatically reduces oxidative capacity in these hearts11 and
induces a foetal gene programme resulting in a metabolic phenotype
closer to the immature heart, where glycolysis is more important for
energy production relative to substrate oxidation.12– 14 Nevertheless,
in what would appear to be in contrast to the adverse effects of fatty
acids in adult hearts, Ito et al.15 recently demonstrated that high levels
of fatty acids in the perfusate are capable of enhancing post-ischaemic
energy production and increasing contractile function in isolated
working neonatal rabbit hearts as opposed to adult hearts. That
study provides evidence that in hearts with limited oxidative capacity
increasing exogenous energy substrate supply and boosting fatty acid
oxidation, which generates 20% more ATP per metabolized C-atom
than glucose oxidation, quickly normalizes energy production. It
further raises the possibility that fatty acid oxidation may be also es-
sential in improving post-ischaemic recovery in the conditioned
infarct-remodelled myocardium. However, this correlate has not
been explored directly so far. Hence, we set out to determine oxida-
tive metabolism in working rat hearts 6 weeks after coronary artery
ligation. We hypothesized that infarct-remodelled hearts because of
their limited oxidative capacity would enhance post-ischaemic
energy production after conditioning by selective up-regulation of
fatty acid rather than glucose oxidation. Conditioning of the hearts
was achieved using the preconditioning-mimicking anaesthetic sevo-
flurane, an agent previously shown to be effective in normal and
infarct-remodelled myocardium.8,16
Our study now shows for the first time that conditioned
infarct-remodelled hearts with marked limitations in oxidative cap-
acity preserve post-ischaemic energy metabolism by activation of
fatty acid and not glucose oxidation and mobilization of surplus
energy from accumulated endogenous triglyceride stores, which
closely correlated with recovery.
2. Methods
The investigation conforms to the Guide for the Care and Use of Laboratory
Animals published by the US National Institutes of Health (NIH Publica-
tion, 8th Edition, 2011) and was approved by the University of Alberta
Animal Policy and Welfare Committee. All the chemicals were from
Sigma-Aldrich Canada Ltd. (Oakville, ON, Canada), unless otherwise
stated.
2.1 Coronary artery ligation to promote
ventricular remodelling and echocardiography
Ligation of the left anterior descending coronary artery (CAL) and sham
operations were performed in 8-week-old 200 g male Sprague–Dawley
rats, as previously described.17 Ligation was performed under inhalational
anaesthesia with isoflurane. Adequacy of anaesthesia was confirmed by
the loss of the righting reflex during surgery. Buprenorphine (0.05 mg/
kg) was administered sc every 12 ho for the first three post-operative
days. The rats were kept for additional 6 weeks fed with normal diet,
and cardiac function was assessed using echocardiography under light iso-
flurane anaesthesia, using a Vevo 770 high-resolution imaging system
equipped with a 30 MHz transducer (RMV-707B, VisualSonics, Toronto,
Canada). The function of all the hearts was further evaluated ex vivo in
the isolated working heart mode. Morphological and biochemical
markers of ventricular remodelling were also determined.
2.2 Working heart perfusions
Six weeks after ligation or sham operation, the rats were euthanized with
pentobarbital (150 mg/kg, ip). Each heart was rapidly removed and per-
fused in the working mode with Krebs–Henseleit solution containing
glucose (11 mM), palmitate (1.2 mM, pre-bound to 3% bovine serum
albumin), and insulin 100 mU/L.8 The hearts were subjected to 15 min
of no-flow ischaemia and 30 min of reperfusion (Supplementary material
online, Figure S1). Sevoflurane (0.5 mM) bubbled into the perfusate was
used to induce protection. The protocols are detailed in the Supplemen-
tary material online.
2.3 Metabolic flux measurements of glucose
and fatty acid oxidation
Glucose and fatty acid oxidation were determined by perfusing the hearts
with [U-14C]glucose and [9,10-3H]palmitate, respectively.8 Total myocar-
dial 14CO2 production and
3H2O production were determined every
10 min. Rates expressed as mmol/g dry wt/min were calculated for each
time interval and were averaged for pre- and post-ischaemic periods.
Differences between averaged pre-ischaemic and averaged post-ischaemic
values were computed for each heart.
2.4 Citrate synthase activity
To determine the capacity of the tricarboxylic acid cycle, the activity of
the mitochondrial matrix marker enzyme citrate synthase (CS) was mea-
sured at 412 nm by monitoring the formation of thionitrobenzoate, as
detailed in the Supplementary material online.
2.5 Pyruvate dehydrogenase complex activity
Pyruvate dehydrogenase activity was measured by a radioisotopic-coupled
enzyme assay, which determines the ratio PDHactive/PDHtotal. This ratio
gives an indication of the phosphorylation state of pyruvate dehydrogenase
E1a subunit. Details are provided in the Supplementary material online.
2.6 Hydroxyacyl-coenzyme A dehydrogenase
activity
Enzyme activity was measured under standardized optimal conditions using
continuous kinetic determination. One unit of activity is defined as enzyme
activity converting 1.0 mmol of acetoacetyl-CoA into b-OH-butyryl-CoA in
the presence of NADH per minute per mg protein at 378C (pH 7.3).
2.7 Triglyceride hydrolase activity
Frozen ventricular tissue was homogenized in ice-cold lysis buffer
containing 0.25 M sucrose, 1 mM EDTA, 1 mM dithiothreitol, 20 mg/mL
leupeptin, 2 mg/mL antipain, and 1 mg/mL pepstatin (pH 7.0) and spun
at 20 000 g at 48C for 30 min.18 The infranatant (100 mg of protein in
100 mL lysis buffer) was incubated with 100 mL of substrate in a water
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bath for 60 min at 378C. The reaction was terminated by the addition of
3.25 mL of methanolchloroform-heptane (10:9:7 [vol/vol/vol]) and 1 mL
of 0.1 M potassium carbonate—0.1 M boric acid, pH 10.5, and the
samples were vigorously mixed for extraction. After centrifugation
(800 g, 20 min), radioactivity in 1 mL of the upper phase was determined
by liquid scintillation counting. The triglyceride substrate contained
33 nmol of glycerol trioleate/assay (glycerol tri[9,10(n)-3H]oleate 40
000 cpm/nmol) in 50 mM potassium phosphate buffer, pH 7.0, and 2.5%
defatted bovine serum albumin and was prepared by sonication on ice.
2.8 High-resolution respirometry
in permeabilized cardiac fibres
Respiration measurements were performed in saponin-permeabilized
fibres prepared from freshly excised left ventricular apex of perfused
hearts, using the Oroboros Oxygraph 2K system (Oroboros, Innsbruck,
Austria). Characterization of the mitochondrial respiratory complexes
was obtained using the following substrates in the presence of 5 mM
ADP (State 3) and the absence of ADP (State 2): pyruvate (5 mM)/
malate (2 mM), glutamate (10 mM)/malate (2 mM), succinate (10 mM), as-
corbate (2 mM)/tetramethyl-phenylenediamine dihydrochloride (TMPD;
0.5 mM), and palmitoylcarnitine (20 mM)/malate (2 mM). The respirome-
try data were normalized to mitochondrial content (CS activity). The
protocols are provided in the Supplementary material online in detail.
2.9 Mass spectrometry for acylcarnitine
profiling
From all the hearts, tissue levels of thirty-two acylcarnitine species were
measured using electrospray ionization tandem mass spectrometry.19
Acylcarnitines were extracted from heart tissue with methanol and quan-
tified using eight isotopically labelled internal standards (Cambridge Iso-
topes Laboratories, Andover, MA, USA). Precursor ions of an m/z of 85
in the mass range m/z 150 to 450 were acquired on a PE SCIEX API
365 LC-ESI-MS/MS instrument (AppliedBiosystems, Foster City, CA,
USA).
2.10 HPLC-fluorescence spectrometry
for short-chain CoA ester determinations
Frozen rat heart tissue was homogenized in a 6% perchloric acid/1 mM
1,4-dithiothreitol solution.19 The homogenate was incubated on ice for
20 min and centrifuged at 12 000 g for 15 min. The supernatant was col-
lected and incubated on ice for 4–5 h. Short-chain CoA (acetyl-CoA,
malonyl-CoA, succinyl-CoA, and free CoA) concentrations were deter-
mined using Waters AcQuity with PDA elDetector, sample manager,
and Binary solvent manager by high-performance liquid chromatography
(Waters, ON, Canada).
2.11 Determination of tissue triglyceride
content and incorporation of
[9,10-3H]palmitate into triglycerides
After chloroform/methanol extraction of lipids from cardiac tissue, trigly-
ceride content was quantified colorimetrically with the enzymatic assay kit
L-Type Triglyceride M (Wako Pure Chemical Industries, Richmond, VA,
USA).19 Incorporation of [9,10-3H]palmitate into triglycerides was
counted.
2.12 Determination of tissue glycogen content
and incorporation of [U-14C]glucose into
glycogen
Myocardial glycogen content (mmol glucosyl units/g dry wt) was deter-
mined by powdering heart tissue samples and subjecting them to alkaline
extraction by 30% KOH followed by ethanol precipitation and acid hy-
drolysis (2N H2SO4).
19 This was followed by measurement of glucose
content in these extracts. The amount of radiolabelled glucose in glycogen
extracts was also determined to evaluate the degree of incorporation of
radiolabelled glucose into glycogen corresponding to the rate of glycogen
synthesis.
2.13 Immunoblotting and ELISA
Immunoblots were performed as detailed in the Supplementary material
online. For sirtuin-1 (Sirt1), PPARa and PGC-1a immunoblots, nuclear
fractions using nuclear extraction kit NE-PERw Nuclear Thermo Scientific
(Rockford, IL, USA), and for Sirt3 immunoblots crude mitochondrial frac-
tions were prepared. The antibodies used, and their sources, are provided
in the Supplementary material online. Nuclear presence of PPARa
(CSB-E09755r, Cusabio Biotech Co Ltd, Wuhan, Hubei, China) and
PGC-1a (CSB-EL018426RA, Cusabio Biotech Co Ltd, Wuhan, Hubei,
China) was measured by ELISA following the manufacturer’s instructions.
2.14 HIF1a transcription factor assay
Nuclear extracts were prepared from frozen tissue using the NE-PER
Nuclear and Cytoplasmic Extraction Reagent Kit (Product No. 78833;
Thermo Scientific). Electrophoretic mobility shift assay was performed
using the HIF1a LightShift Chemiluminescent electrophoretic mobility
shift assay kit (10006910, Cayman Chemical Company, MI, USA)
2.15 Statistical analysis
Values are given as mean (SD) or median (25th, 75th percentile) depend-
ing on the underlying data distribution for the indicated number of inde-
pendent observations (n). The significance of differences in
haemodynamic and metabolic variables among groups was determined
by Student’s t-test (two groups) or by analysis of variance (ANOVA) fol-
lowed by the Student–Newman–Keuls method for post hoc analysis or by
non-parametric methods (the Mann–Whitney rank sum test or the
Kruskal–Wallis test), depending on the underlying data distribution. To
test the association between haemodynamic changes and triglyceride
and glycogen tissue contents and the association between Sirt1 and
PGC-1a, linear regression analyses were performed. The correlation co-
efficient R and the corresponding P-value are reported. Differences are
considered significant if P, 0.05. SigmaStat (version 3.5; Systat Software,
Inc., Chicago, IL, USA) was used for the analyses.
3. Results
3.1 Infarct-remodelled hearts exhibit
metabolic deficits in tricarboxylic acid cycle
capacity and mitochondrial respiration
Six weeks after ligation of the coronary artery, the ratio of heart
weight to body weight and the molecular markers of hypertrophy
and remodelling were significantly increased (Table 1 and Supplemen-
tary material online, Figure S2). Echocardiography revealed reduced
ejection fraction and fractional shortening, and increased wall thick-
ness and diastolic and systolic inner diameters of the left ventricle
(Table 1). Measurement of metabolic capacities showed marked re-
duction in tricarboxylic acid cycle capacity (Table 1) and in mitochon-
drial respiration with various substrates, including glutamate/pyruvate/
malate (complex I), succinate (complex II), palmitoylcarnitine/malate
(b-oxidation), and ascorbate/TMPD (complex IV) (Table 2). Oxygen
consumption in the absence of ADP (‘leak respiration’) was elevated
and respiratory control ratio (‘oxidative capacity’) was accordingly
reduced in infarct-remodelled hearts. Pyruvate dehydrogenase activity
and hydroxyacyl-CoA dehydrogenase activity were unchanged
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between infarct-remodelled and sham hearts under aerobic baseline
conditions (Table 1).
3.2 Metabolic responses to ischaemic injury
are different in protected
infarct-remodelled vs. sham hearts
Consistent with echocardiography, ex vivo-remodelled working hearts
exhibited reduced left ventricular work at baseline (Figure 1A). Fifteen
minutes of ischaemia followed by 30 min of reperfusion reduced peak
systolic pressure, cardiac output, and left ventricular work in untreat-
ed sham and infarct-remodelled hearts (Figure 1B, Supplementary ma-
terial online, Table S1). None of the hearts experienced sustained
ventricular fibrillation and thus, all the hearts could be used for meta-
bolic analysis. Sevoflurane markedly increased functional recovery in
both sham and infarct-remodelled hearts (Figure 1). Baseline glucose
and fatty acid oxidation and acetyl-CoA turnover (TCA cycle activity)
were similar in sham and infarct-remodelled hearts (Table 3).
However, fatty acid oxidation was markedly reduced after ischae-
mia/reperfusion in infarct-remodelled but not in sham hearts. Protec-
tion with sevoflurane restored fatty acid oxidation to 84% of baseline
values in infarct-remodelled hearts, securing energy production as evi-
denced by increased acetyl-CoA turnover (Table 3). Consistent with
this notion, acetyl-CoA tissue levels also significantly increased in pro-
tected infarct-remodelled hearts (Table 4).
3.3 Infarct-remodelled hearts secure
post-ischaemic energy production by
activation of b-oxidation and mobilization
of fatty acids from endogenous triglyceride
stores
In accordance with the metabolic flux measurements in isolated
hearts, high-resolution respirometry revealed increased oxygen flux
in permeabilized conditioned remodelled left ventricular muscle
fibres when using palmitoylcarnitine/malate as substrate providing evi-
dence for improved b-oxidation (Figure 2A, Table 2). Since oxygen
consumption is measured in these experiments under unloaded
resting conditions, it can be concluded that increased b-oxidation is
a cause and not a consequence of the observed improved cardiac
function. Interestingly, increased b-oxidation in protected
infarct-remodelled hearts occurred independently of malonyl-CoA
tissue levels (Table 4). While total hydroxyacyl-CoA dehydrogenase
activity, as measured under in vitro conditions, was unchanged after
ischaemia/reperfusion between protected and unprotected sham
and infarct-remodelled hearts (Figure 2B), acylcarnitine profiling
revealed a lower ratio of C16:1+C16OH/C14 carnitine species, a
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Table 1 Model characteristics
Sham CAL P-value
Measures of cardiac remodelling
Heart weight/body weight 0.380 (0.037) 0.426 (0.051) 0.02
ANP protein level 0.09 (0.07) 0.44 (0.16) ,0.001
a-skeletal actin protein level 1.14 (0.31) 1.79 (0.57) 0.01
Measures of metabolic capacity
Citrate synthase activity (mmol mL21 min21 mg21) 24.5 (3.0) 17.5 (2.8) ,0.001
Total pyruvate dehydrogenase activity (mmol/g protein/min) 1.19 (0.28) 1.25 (0.53) 0.83
Pyruvate dehydrogenase activity (ratio active/total) 0.74 (0.13) 0.74 (0.14) 0.95
Hydroxyacyl-CoA dehydrogenase activity (mmol/g protein/min) 7.22 (3.33) 6.26 (0.62) 0.59
Echocardiography data
M-mode measures
Ejection fraction (EF, %) 73.8 (66.8; 76.0) 56.9 (46.4; 60.1) 0.001
Fractional shortening (ES, %) 44.2 (38.7; 46.7) 31.4 (24.9; 33.67) 0.002
Average cardiac output (CO, mL/min) 100 (21) 80 (17) 0.07
Wall measurements
Interventricular septum thickness, diastole (mm) 1.9 (0.1) 2.1 (0.2) 0.009
Interventricular septum thickness, systole (mm) 3.1 (0.3) 3.2 (0.3) 0.84
Left ventricular inner diameter, diastole (mm) 8.6 (0.6) 9.8 (0.8) 0.004
Left ventricular inner diameter, systole (mm) 4.9 (0.7) 7.0 (0.9) ,0.001
Left ventricular posterior wall thickness, diastole (mm) 1.9 (0.1) 2.1 (0.2) 0.023
Left ventricular posterior wall thickness, systole (mm) 3.1 (0.3) 3.2 (0.3) 0.61
Tissue Doppler data
TEI index 0.80 (0.09) 0.89 (0.17) 0.21
E/E′ 17.5 (3.8) 25.0 (7.6) 0.03
E′/A′ 1.0 (0.3) 0.9 (0.2) 0.45
Data are presented as mean (SD) or median (25th; 75th percentile).
ANP, atrial natriuretic peptide; E/E′ , ratio of mitral velocity to velocity of the mitral annulus in early diastole; E′/A′ , early (E′) to late (A’) diastolic velocity ratio of mitral annulus; Sham,
sham-operated hearts (n ¼ 8); CAL, infarct-remodelled hearts (n ¼ 8).
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protein-independent measure of long-chain hydroxyacyl-CoA de-
hydrogenase activity, in protected infarct-remodelled hearts
(Figure 2C, Supplementary material online, Table S2). The ratio of
C0/C16 + C18 carnitine species, an index of reduced fatty acid trans-
port into mitochondria by the carnitine palmitoyl transferase system,
was significantly increased in protected sham but not in
infarct-remodelled hearts (Figure 2D). Sevoflurane protection also
reduced accumulation of C18, OH-, and unsaturated acylcarnitine
intermediates in sham and OH-acylcarnitine species in
infarct-remodelled hearts. It further reduced complex II activity in
sham hearts and complex I activity in infarct-remodelled hearts
(Table 2). Consistent with previous reports,20 unprotected
infarct-remodelled hearts exhibited higher baseline triglyceride con-
tents (cold triglycerides) (Figure 3A), which were normalized after is-
chaemia/reperfusion in protected infarct-remodelled hearts with
improved flux in b-oxidation. Incorporation of radioactive palmitate
into triglyceride was slightly (but significantly P, 0.004) reduced in
protected sham hearts, but unaffected in infarct-remodelled hearts
(Figure 3A). Sevoflurane protection also preserved glycogen tissue
contents and enhanced incorporation of radioactive glucose into
glycogen in both sham and infarct-remodelled hearts (Figure 3B).
Importantly, triglyceride tissue content inversely and closely corre-
lated with changes in left ventricular work in infarct-remodelled but
not in sham hearts, consistent with the concept that additional fatty
acids were mobilized from endogenous triglyceride stores boosting
energy production (Figure 4A). However, triglyceride hydrolase activ-
ity was unchanged in protected remodelled hearts and phosphoryl-
ation of hormone-sensitive lipase at Ser660, a well-known activity
controlling site,21 was not increased (Supplementary material online,
Figure S3). To further elucidate the protective role of fatty acid mobil-
ization in remodelled hearts, additional experiments were performed
using 2.4 mM palmitate in the perfusate mimicking increased supply of
fatty acids from triglyceride stores. This higher concentration of palmi-
tate (2.4 mM) in the perfusate increased post-ischaemic recovery
from 22 to 73% (P ¼ 0.004) in remodelled hearts (Supplementary
material online, Figure S4), suggesting that mobilization of fatty acids
indeed contributes to protection. In contrast to triglyceride tissue
contents, glycogen tissue levels directly correlated with changes
in left ventricular work in sham and in infarct-remodelled hearts.
This is in accordance with their role of an ischaemic injury marker
rather than an efficient energy source under ischaemic conditions
(Figure 4B).
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 2 High-resolution respirometry in cardiac fibres
Sham/aerobic CAL/aerobic Sham/IR Sham1 SEV/IR CAL/IR CAL 1 SEV/IR
Oxygen consumption in the presence of ADP
Glutamate/malate 9.17 (1.13) 6.17 (2.04) 5.10 (1.75) 3.27 (1.39) 7.19 (1.62) 5.34 (1.14)
P-value 0.026 0.104 0.039
Pyruvate/malate 10.33 (1.62) 6.86 (1.52) 6.51 (1.57) 6.03 (1.67) 8.86 (2.37) 8.67 (1.89)
P-value 0.014 0.656 0.878
Glutamate/malate/succinate 18.34 (2.70) 10.83 (3.04) 8.63 (1.23) 6.72 (1.10) 12.12 (3.20) 9.53 (2.51)
P-value 0.006 0.033 0.137
Succinate 11.30 (1.48) 7.34 (2.14) 5.80 (1.01) 4.81 (0.85) 7.96 (2.13) 6.26 (0.92)
P-value 0.013 0.135 0.098
Palmitoylcarnitine/malate 3.72 (1.44) 2.06 (0.95) 2.13 (0.39) 2.38 (0.54) 2.37 (0.60) 3.34 (0.92)
P-value 0.089 0.416 0.042
Ascorbate/TMPD 26.24 (4.99) 19.34 (6.49) 16.69 (11.1;21.6) 12.49 (11.7;14.9) 22.87 (7.31) 24.29 (7.66)
P-value 0.112 0.548 (Mann–Whitney) 0.739
Oxygen consumption in the absence of ADP
Glutamate/malate 0.81 (0.13) 1.71 (0.64) 1.41 (1.26;1.84) 1.26 (1.18;1.47) 2.32 (0.42) 2.08 (0.36)
P-value 0.017 0.310 (Mann–Whitney) 0.305
Pyruvate/malate 0.91 (0.73;1.31) 2.34 (1.99;2.64) 2.39 (0.52) 1.98 (0.78) 3.04 (0.78) 3.12 (1.11)
P-value 0.016 (Mann–Whitney) 0.365 0.885
Palmitoylcarnitine/malate 0.78 (0.13) 1.20 (0.26) 1.11 (0.28) 1.13 (0.22) 1.41 (0.39) 1.80 (0.51)
P-value 0.017 0.935 0.154
Respiratory control ratio
Glutamate/malate 11.58 (2.37) 3.72 (0.50) 3.22 (0.99) 2.31 (0.45) 3.09 (0.29) 2.55 (0.22)
P-value ,0.001 0.097 0.003
Pyruvate/malate 10.93 (2.41) 2.97 (0.36) 2.74 (0.46) 3.15 (0.43) 3.16 (0.34) 2.91 (0.51)
P-value ,0.001 0.179 0.313
Palmitoylcarnitine/malate 4.85 (1.97) 1.68 (0.58) 1.97 (0.38) 2.02 (0.13) 1.72 (0.35) 1.89 (0.33)
P-value 0.018 0.821 0.386
The measured oxygen flux (normalized to citrate synthase activity) is expressed as nmol O2*s
21/CS. Data are presented as mean (SD) or median (25th percentile; 75th percentile). N ¼ 5
in all sham groups (aerobic and ischaemia/reperfusion), n ¼ 4 in CAL/aerobic, n ¼ 7 in CAL/IR, n ¼ 6 in CAL + SEV/IR.
sham/IR, sham hearts exposed to ischaemia/reperfusion without treatment; Sham + SEV/IR, sham hearts exposed to ischaemia/reperfusion with sevoflurane; CAL/IR, infarct-remodelled
hearts exposed to ischaemia/reperfusion without treatment; CAL + SEV/IR, infarct-remodelled hearts exposed to ischaemia/reperfusion with sevoflurane.
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3.4 Infarct-remodelled hearts exhibit
higher nuclear levels of PPARa and PGC-1a
and a deficit in the HIF-1a hypoxic response
indicating a loss of metabolic flexibility
To dissect the regulation of energy metabolism in sham vs.
infarct-remodelled hearts, we determined nuclear PPARa and
PGC-1a protein levels. Infarct-remodelled hearts exhibited markedly
higher nuclear PPARa and PGC-1a levels (Figure 5A) than sham
hearts, while no regulation in response to sevoflurane conditioning
or ischaemia/reperfusion was evident (data not shown). HIF-1a, a
transcription factor that regulates glycolytic gene expression, was
reduced in infarct-remodelled hearts compared with sham hearts
(Figure 5A). Remodelled hearts exposed to ischaemia/reperfusion
did not exhibit HIF-1a regulation as opposed to sham hearts
(Figure 5B). We further determined nuclear Sirt1 and mitochondrial
Sirt3 expression in infarct-remodelled and sham hearts, since mito-
chondrial Sirt3 was previously reported to deacetylate and activate
hydroxyacyl-CoA dehydrogenase,22 while nuclear Sirt1 was reported
to deacetylate and inactivate HIF-1a.23 Sirt1 was increased in
infarct-remodelled vs. sham hearts, and there was only a minor regu-
lation in response to conditioning (Supplementary material online,
Figure S5). Sirt3 levels were not different between infarct-remodelled
and sham hearts. Sirt3 decreased more in infarct-remodelled hearts
after ischaemia/reperfusion (Supplementary material online, Figure
S5), but there was no regulation in response to conditioning. Consist-
ent with previous reports on PGC-1a deacetylation and activation by
Sirt1,24 Sirt1 levels correlated closely with nuclear PGC-1a
(Figure 5C). Together, the observed metabolic phenotype in remod-
elled hearts is consistent with a loss of metabolic flexibility and indi-
cates a shift in energy metabolism towards fatty acid oxidation.
4. Discussion
Our study examined the bioenergetics in infarct-remodelled hearts in
the presence and the absence of pharmacological protection, which
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Table 3 Rates of glucose oxidation, fatty acids oxidation, and acetyl-CoA production
Sham/IR Sham1 SEV/IR CAL/IR CAL 1 SEV/IR
GOX (mmol/g dry wt min) Before ischaemia 0.748 (0.243) 0.771 (0.316) 0.628 (0.162) 0.698 (0.168)
Reperfusion 0.471 (0.179) 0.639 (0.115) 0.662 (0.221) 0.579 (0.212)
DGOX (mmol/g dry wt min) 20.276 (0.300) 20.131 (0.268) 0.034 (0.301) 20.119 (0.088)
P-value 0.399 0.259
FOX (mmol/g dry wt min) Before ischaemia 0.898 (0.236) 0.990 (0.264) 0.878 (0.142) 0.749 (0.141)
Reperfusion 0.555 (0.473) 0.901 (0.207) 0.296 (0.254) 0.629 (0.230)
DFOX (mmol/g dry wt min) 20.343 (0.358) 20.089 (0.124) 20.571 (0.227) 20.120 (0.152)
P-value 0.131 0.002
acCoA (mmol/g dry wt min) Before ischaemia 8.680 (2.004) 9.397 (2.108) 8.333 (1.350) 7.311 (1.245)
Reperfusion 5.344 (4.168) 8.488 (1.807) 3.616 (2.405) 6.186 (1.970)
DacCoA (mmol/g dry wt min) 23.337 (3.389) 20.909 (0.698) 24.717 (2.312) 21.125 (1.374)
P-value 0.116 0.008
Data are presented as mean (SD). N ¼ 6 in all groups.
GOX, glucose oxidation rate (mmol/g dry wt.min); FOX, fatty acids oxidation rate (mmol/g dry wt.min); acCoA, acetyl coenzyme A production rate (mmol/g dry wt.min); Sham/IR, sham
hearts exposed to ischaemia/reperfusion without treatment; sham + SEV/IR, sham hearts exposed to ischaemia/reperfusion with sevoflurane; CAL/IR, infarct-remodelled hearts exposed
to ischaemia/reperfusion without treatment; CAL + SEV/IR, infarct-remodelled hearts exposed to ischaemia/reperfusion with sevoflurane.
Figure 1 Functional recovery in sham and remodelled hearts.
(A) LVW, left ventricular work. (B) DLVW, corresponding change in
LVW; Sham/IR, unprotected sham hearts exposed to ischaemia/reper-
fusion alone without treatment; Sham + SEV/IR, protected sham
hearts exposed to sevoflurane and ischaemia/reperfusion; CAL/IR, un-
protected remodelled hearts exposed to ischaemia/reperfusion alone
without treatment; CAL + SEV/IR, protected remodelled hearts
exposed to sevoflurane and ischaemia/reperfusion. *P, 0.001 base-
line sham vs. baseline CAL (aerobic). #P, 0.001 Sham + SEV/IR or
CAL + SEV/IR vs. Sham/IR or CAL/IR.
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was achieved by administration of a preconditioning-mimicking anaes-
thetic known to be effective in the infarct-remodelled myocar-
dium.17,25 Since cardiac remodelling markedly changes gene and
protein expression promoting a metabolic phenotype more similar
to the foetal or immature heart,11 –14 we hypothesized that condi-
tioned remodelled hearts would adapt to ischaemia/reperfusion dif-
ferentially at metabolic level. The novel finding of this study is that
conditioned remodelled hearts with limited oxidative capacity
secure post-ischaemic energy production by activation of fatty acid
and not glucose oxidation and by mobilization of surplus fuel from
accumulated intracellular triglyceride stores. We previously showed
that sevoflurane rather decreases fatty acid oxidation excluding the
possibility that the observed metabolic shift is caused by an intrinsic
metabolic effect of sevoflurane itself.19 Since we determined
Figure 2 b-Oxidation in sham and remodelled hearts. (A) Oxygen flux in sham and remodelled cardiac fibres as measured by high-resolution
respirometry. (B) hydroxyacyl-CoA dehydrogenase (HADH) activity as determined by the in vitro assay. (C) Protein-independent measure of
hydroxyacyl-CoA dehydrogenase activity reflecting enzyme activity under physiological conditions using acylcarnitines profiling. (D) Ratio of C0/
C16 + C18 carnitine species, an index of the carnitine palmitoyl transferase system. Data are mean (SD) or median (25th, 75th percentile). Sham/
IR, unprotected sham hearts exposed to ischaemia/reperfusion without treatment. Sham + SEV/IR, protected sham hearts exposed to sevoflurane
and ischaemia/reperfusion; CAL/IR, unprotected remodelled hearts exposed to ischaemia/reperfusion alone without treatment; CAL + SEV/IR, pro-
tected remodelled hearts exposed to sevoflurane and ischaemia/reperfusion.
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Table 4 Short-chain acyl-CoA tissue levels
Sham/IR Sham1 SEV/IR CAL/IR CAL 1 SEV/IR
Free CoA (nmol/g dry wt) 864 (181) 1098 (138) 754 (206) 974 (178)
P-value 0.030 0.067
Malonyl-CoA (nmol/g dry wt) 12.0 (3.1) 15.9 (2.4) 10.2 (2.0) 12.5 (2.5)
P-value 0.039 0.086
Acetyl-CoA (nmol/g dry wt) 134 (53) 174 (56) 91 (25) 128 (31)
P-value 0.236 0.032
Succinyl-CoA (nmol/g dry wt) 216 (71) 308 (81) 175 (94) 231 (62)
0.064 0.241
Data are presented as mean (SD). N ¼ 6 in all groups except CAL/IR (n ¼ 7).
Sham/IR, sham hearts exposed to ischaemia/reperfusion without treatment; Sham + SEV/IR, sham hearts exposed to ischaemia/reperfusion with sevoflurane; CAL/IR, infarct-remodelled
hearts exposed to ischaemia/reperfusion without treatment; CAL + SEV/IR, infarct-remodelled hearts exposed to ischaemia/reperfusion with sevoflurane.
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mitochondrial function under unloaded resting conditions, we also
provide evidence that increased b-oxidation is a cause and not a con-
sequence of the observed improved cardiac function in conditioned
remodelled hearts. Our results are to a certain extent in contrast
to those of previous studies,12,14 but may be related to the unique
metabolic profile of infarct-remodelled hearts, which exhibit
increased PPARa-PGC-1a but reduced and defective HIF-1a signal-
ling. In the current study, protected sham hearts only showed
minor metabolic changes with some recovery of glucose and fatty
acid oxidation in response to 15 min of ischaemia, but clearly exhib-
ited reduced uptake of fatty acids into mitochondria. This is consistent
with the previous studies from our laboratory with more sustained is-
chaemia (20 min) using the same experimental model and protocol,8
which have demonstrated a significant reduction in fatty acid and a
concomitant increase in glucose oxidation in non-remodelled
healthy myocardium. We believe that these and the present findings
highlight a key concept in cardiac metabolism whereby diseased
hearts with reduced or limited oxidative capacity are unable to
switch to the ‘oxygen-sparing’ metabolic programme under metabolic
stress, i.e. favouring glucose over fatty acids as fuel. Collectively, the
metabolism in infarct-remodelled hearts clearly mirrors the loss of
metabolic flexibility in energy production and fundamentally differs
from healthy hearts.
A better understanding of the relationships between energy metab-
olism, contractility, and anti-ischaemic tolerance in infarct-remodelled
hearts could help identify novel approaches to limiting cardiac injury
or preventing the progression to heart failure. Energy metabolism
was previously examined in hearts remodelled chronically.26
Whether abnormal metabolism is an adaptive response that slows
progression to failure or whether it is a maladaptive response that
accelerates the development of heart failure has not been resolved.
However, in failing hearts, low rates of fatty acid oxidation may under-
lie the observed increased reliance on glucose as an energy source,
which potentially helps maintain rates of acetyl-CoA production.
Our study now shows for the first time that infarct-remodelled
hearts with significant deficits in oxidative phosphorylation and coun-
terregulatory PPARa-PGC-1a up-regulation but reduced and defect-
ive hypoxic HIF-1a signalling boost fatty acid and not glucose
oxidation after conditioning against ischaemia/reperfusion injury. It is
remarkable that under aerobic baseline conditions infarct-
remodelled hearts in our study did not exhibit changes in partitioning
of glucose and fatty acid oxidation compared with sham hearts despite
their deficits in energy production. This is more striking so as
PPARa-PGC-1a, which promotes fatty acid oxidation, was significant-
ly up-regulated and HIF-1a activity and its hypoxic response were
blunted. Inhibition of HIF-1a signalling because of p53 accumulation
with subsequent cardiac dysfunction was previously reported in
pressure-overloaded hearts progressing from hypertrophy to heart
failure.27 Alternatively, increased nuclear Sirt1 may have deacetylated
and inactivated HIF-1a,23 which is however at odds with other
reports showing that Sirt1 does not affect HIF-1a but deacetylates
and activates HIF-2a.28 On the other hand, reduced HIF-1a activity
in infarct-remodelled hearts may be regarded as an endogenous pro-
tective strategy of the heart since chronic HIF-1a activation is
observed in patients with end-stage heart failure and reportedly accel-
erates progression to heart failure.29 It is noteworthy that in our study
coupling between PGC-1a and HIF-1a signaling, which is normally
functional in healthy oxidative tissue,30 was absent in infarct-remod-
eled hearts. However, this is consistent with previous reports
increased Sirt1 closely correlated with nuclear PGC-1a levels.31
Nonetheless, upon exposure to ischaemia/reperfusion, conditioned re-
modelled hearts replenished their citric acid cycle with C2-bodies from
activated fatty acid oxidation despite its oxygen-wasting effects, unco-
vering their intrinsic preference in substrate oxidation. Restoration of
energy production was neither at the expense of glucose oxidation,
which remained unchanged, nor regulated by malonyl-CoA, the key in-
hibitor of fatty acid transport into mitochondria, implying that this
metabolic change occurred independently of the ‘Randle cycle’.32
Since hydroxyacyl-CoA dehydrogenase is the critical rate-limiting
enzyme in fatty acid oxidation and its enhanced activity was previously
reported to foster mitochondrial respiration and improve contractile
function in failing hearts,33 we determined its activity in sham and
infarct-remodelled hearts. However, we were unable to detect
increased activity in conditioned remodelled hearts, which clearly
exhibited increased fatty acid oxidation, most probably because the
assay used measures only enzyme activity under non-physiological con-
ditions. Hence, we employed a protein-independent method using acyl-
carnitine profiling and calculated the ratio of C16:1+
Figure 3 Hot and cold constituents of triglycerides (TG) and
glycogen in sham and remodelled hearts. (A) Higher cold TG
levels in remodelled hearts, which are reduced to sham heart
levels in protected remodelled hearts (#P ¼ 0.005). Reduced incorp-
oration of hot palmitate into TG was observed in sham + SEV/IR vs.
sham/IR (*P ¼ 0.004). (B) Higher glycogen levels in protected sham
(cold #P ¼ 0.007, hot *P ¼ 0.03) and remodelled hearts (cold
#P ¼ 0.025). Data are mean (SD). Sham/IR, unprotected sham
hearts exposed to ischaemia/reperfusion without treatment. Sham +
SEV/IR, protected sham hearts exposed to sevoflurane and ischae-
mia/reperfusion; CAL/IR, unprotected remodelled hearts exposed
to ischaemia/reperfusion alone without treatment; CAL + SEV/IR,
protected remodelled hearts exposed to sevoflurane and ischae-
mia/reperfusion.
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C16OH/C14 carnitine species, which inversely correlates with the ac-
tivity of long-chain hydroxyacyl-CoA dehydrogenase, the initial step of
palmitate oxidation.34 Consistent with our data from high-resolution
respirometry, these measurements provide evidence for an increased
activity of the long-chain hydroxyacyl-CoA dehydrogenase in condi-
tioned vs. non-conditioned remodelled hearts. Sirt3, a mitochondrial
NAD+-dependent protein deacetylase, was recently reported to acti-
vate long-chain hydroxyacyl-CoA dehydrogenase.22 Although we did
not observe changes in Sirt3 expression, it is possible that changes in
NAD+ levels in conditioned remodelled hearts activated Sirt3 and sub-
sequently deacetylated hydroxyacyl-CoA dehydrogenase. Alternative-
ly, since long-chain hydroxyacyl-CoA dehydrogenase activity was
increased despite complex I inhibition in conditioned remodelled
hearts and inhibition of the respiratory chain should rather decelerate
than accelerate b-oxidation,35 we suspect that the observed increased
long-chain hydroxyacyl-CoA dehydrogenase activity in conditioned
remodelled hearts might be a direct effect of the conditioning-induced
protection on the integrity of the inner mitochondrial membrane,36
where the four enzymes of b-oxidation (acyl-CoA dehydrogenase,
enoyl-CoA hydrates, hydroxyacyl-CoA dehydrogenase, and thiolase)
form a highly efficient multi-functional complex for fatty acid oxidation.
Myocardial triglycerides form a critical energy reservoir. In fact,
fatty acids released by hydrolysis significantly contribute to myocardial
ATP generation.37 Conversely, increased triglyceride lipid content
(‘fatty hearts’) was previously found to be associated with cardiac dys-
function.38 In our study, we detected triglyceride accumulation in
infarct-remodelled hearts, consistent with previous reports.20 But
lipid-loaded infarct-remodelled hearts in our study showed lower
HIF-1a activity compared with sham hearts although most studies
linked increased triglyceride accumulation in diseased myocardium
to enhanced rather than reduced HIF-1a activity.20 Nonetheless,
lipid accumulation in infarct-remodelled hearts might also occur in a
Figure 4 Correlation between triglyceride (TG) and glycogen tissue contents at the end of perfusion with loss in left ventricular work (DLVW). (A)
TG levels do not correlate in sham hearts but show close inverse correlation with the loss of function in infarct-remodelled hearts. (B) Glycogen levels
directly correlate with the loss of function in sham and remodelled hearts. Sham/IR, unprotected sham hearts exposed to ischaemia/reperfusion
without treatment. Sham + SEV/IR, protected sham hearts exposed to sevoflurane and ischaemia/reperfusion; CAL/IR, unprotected remodelled
hearts exposed to ischaemia/reperfusion alone without treatment; CAL + SEV/IR, protected remodelled hearts exposed to sevoflurane and ischae-
mia/reperfusion.
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HIF-1a-independent manner because of lacking interaction between
rarified mitochondria and lipid droplets, potentially reducing fatty
acid metabolism. We here report that conditioned remodelled as
opposed to sham hearts mobilize these accumulated lipid deposits
for energy production under metabolic stress. Interestingly, reduced
capacity to recruit triglycerides for oxidation was reported in
PGC-1a2/2 mice,39 and remodelled hearts in our study exhibited
markedly increased PPARa-PGC-1a levels, suggesting that this meta-
bolic phenotype specifically promotes triglyceride mobilization for
energy production.37 A simple calculation reveals that reduction of
the triglyceride content by 20 mmol/g wet weight, as observed in
our study, generates 480 mmol C2-bodies/g wet weight (assuming
that three palmitate molecules per glycerol would be completely
metabolized) in addition to the energy provided from exogenous
perfusate-borne fatty acids. This amount is substantial and two
times higher than what a healthy heart requires under aerobic condi-
tions in our experimental protocol (240 mmol C2-bodies for 30 min
of reperfusion). It appears that mobilization of fatty acids from trigly-
ceride stores in conditioned remodelled hearts is a passive stoichio-
metric process whereby triglyceride hydrolysis is accelerated by
reduced product feedback inhibition due to increased mitochondrial
b-oxidation in protected vs. unprotected remodelled hearts.40 More-
over, our experiments in remodelled hearts perfused with 2.4 mM
palmitate suggest that increased substrate availability at least partly
compensates for mitochondrial dysfunction and improves post-
ischaemic left ventricular work. Regardless, our results demonstrate
a close inverse correlation between loss of function and triglyceride
content, implying a causal relationship between the generation of
energy from endogenous triglycerides and improved post-ischaemic
functional recovery.
Although the majority of studies suggest that fatty acids and fatty
acid oxidation are detrimental in the context of ischaemia/reperfu-
sion, some findings support the opposite view.15,41–44 Reconciling
the results of these studies and our own findings leads to the
concept that whenever the heart needs a rapid replenishment of crit-
ically depleted energy stores in the presence of apparent (immature
or failing heart) or anticipated (second window of protection) limita-
tions in oxidative phosphorylation capacity, as reflected by PGC-1a
up-regulation, myocardial energy metabolism will be restored by
boosting fatty acid rather than glucose oxidation. The absence of func-
tional HIF-1a signalling may further promote this fuel switch from
glucose to fatty acid metabolism in the diseased myocardium.
Despite its oxygen-wasting effects, fatty acid oxidation has the poten-
tial for rapidly normalizing energy production (8 ATP/C-atom).
Hence, it will be interesting to test in future experiments whether
metabolic support in the form of fatty acid provision may be salutary
to limit the ischaemic damage in energy-depleted infarct-remodelled
hearts. We believe that our findings will be of relevance when target-
ing novel anti-ischaemic metabolic therapies to diseased hearts that
have lost their metabolic flexibility.
Figure 5 Regulation of energy metabolism in sham and infarct-remodelled hearts. (A) Key regulators in remodelled hearts relative to sham hearts
(aerobic). (B) HIF-1a activity in conditioned and non-conditioned sham and remodelled hearts after ischaemia/reperfusion. (C) Correlation between
Sirt1 and PGC-1a. Data are mean (SD) in (A) and (B). *P, 0.05 infarct-remodelled vs. sham hearts (aerobic). Sham/IR, unprotected sham hearts
exposed to ischaemia/reperfusion without treatment. Sham + SEV/IR, protected sham hearts exposed to sevoflurane and ischaemia/reperfusion;
CAL/IR, unprotected remodelled hearts exposed to ischaemia/reperfusion alone without treatment; CAL + SEV/IR, protected remodelled hearts
exposed to sevoflurane and ischaemia/reperfusion.
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In summary, chronically infarct-remodelled conditioned hearts with
limited citric acid cycle capacity and marked deficits in respiratory
chain activities secure post-ischaemic energy production by activation
of fatty acid and not glucose oxidation and by mobilization of fatty
acids from accumulated endogenous triglyceride stores.
Supplementary material
Supplementary material is available at Cardiovascular Research online.
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